Abstract: INTRODUCTION:Schizophrenia is a serious mental health disorder impacting all aspects of life in people living with schizophrenia (PLS), many of whom have a limited response to c...
Abstract: Background: In addition to hallucinations and delusions, people with schizophrenia may exhibit hostility, which is associated with aggressive and violent behavior during acute e...
Abstract: LY03010 (brand name ERZOFRI®) is a newly approved once-a-month paliperidone palmitate (PP1M) extended-release injectable suspension with a differentiated single initial injectio...
Abstract: TV-44749 is an innovative, subcutaneous, long-acting injectable olanzapine for treatment of schizophrenia, designed to provide sustained efficacy and eliminate the risk of post-...
Abstract: Long-acting injectable (LAI) antipsychotics improve adherence and outcomes in adults with schizophrenia. Olanzapine is available as an intramuscular LAI; however, post-injection...
Abstract: TV-44749 is an innovative, subcutaneous long-acting injectable (LAI) olanzapine designed to provide sustained efficacy over the dosing interval without the post-injection deliri...
Abstract: Tardive Dyskinesia Impact Scale (TDIS) evaluates TD symptom impact over the previous 7 days and was a KINECT®3, KINECT®4, and KINECT-PRO outcome. Objectives were to estimate min...
Abstract: Background: Experiential negative symptoms (ENS) of schizophrenia include avolition, asociality, and anhedonia, which impact quality of life and functioning. This study assessed...
Abstract: Rationale: This study assessed treatment patterns and adherence among patients with a diagnosis of schizophrenia receiving antipsychotic medications.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
